Last reviewed 2026-04-19 · How we verify

LDLL600

AOP Orphan Pharmaceuticals AG · Phase 1 active Small molecule

LDLL600 is a Small molecule drug developed by AOP Orphan Pharmaceuticals AG. It is currently in Phase 1 development. Also known as: Landiolol hydrochloride.

At a glance

Generic name	LDLL600
Also known as	Landiolol hydrochloride
Sponsor	AOP Orphan Pharmaceuticals AG
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

LDLL600 CI brief — competitive landscape report
LDLL600 updates RSS · CI watch RSS
AOP Orphan Pharmaceuticals AG portfolio CI

Frequently asked questions about LDLL600

What is LDLL600?

LDLL600 is a Small molecule drug developed by AOP Orphan Pharmaceuticals AG.

Who makes LDLL600?

LDLL600 is developed by AOP Orphan Pharmaceuticals AG (see full AOP Orphan Pharmaceuticals AG pipeline at /company/aop-orphan-pharmaceuticals-ag).

Is LDLL600 also known as anything else?

LDLL600 is also known as Landiolol hydrochloride.

What development phase is LDLL600 in?

LDLL600 is in Phase 1.

Manufacturer: AOP Orphan Pharmaceuticals AG — full pipeline
Also known as: Landiolol hydrochloride
Compare: LDLL600 vs similar drugs
Pricing: LDLL600 cost, discount & access